Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Clinical Research and Equipment Industry Analysis

UpdatedApr 13, 2026
DataAggregated Company Financials
Companies2
  • 7D-4.2%
  • 3M-47.5%
  • 1Y-25.7%
  • YTDn/a

Over the last 7 days, the Clinical Research and Equipment industry has dropped 5.1%, driven by pullbacks from every company within the industry. Overall the industry is down 23% in 12 months. As for the next few years, earnings are forecast to decline by 8.2% per annum.

Industry Valuation and Performance

Has the Danish Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 14 Apr 2026DKK 10.8bDKK 3.1bDKK 1.9b16.6x5.8x3.5x
Thu, 12 Mar 2026DKK 13.2bDKK 3.1bDKK 1.9b21.6x7.1x4.2x
Sat, 07 Feb 2026DKK 14.2bDKK 3.1bDKK 1.9b23.2x7.4x4.5x
Mon, 05 Jan 2026DKK 20.5bDKK 3.1bDKK 1.9b34x10.6x6.5x
Wed, 03 Dec 2025DKK 21.0bDKK 3.1bDKK 1.9b37.9x10.9x6.7x
Fri, 31 Oct 2025DKK 20.6bDKK 3.1bDKK 1.9b38.9x10.6x6.6x
Sun, 28 Sep 2025DKK 17.1bDKK 3.1bDKK 1.9b30.8x8.8x5.4x
Tue, 26 Aug 2025DKK 15.4bDKK 3.1bDKK 1.9b28.5x8x5x
Thu, 24 Jul 2025DKK 15.6bDKK 725.3mDKK 132.6m53x117.8x21.5x
Sat, 21 Jun 2025DKK 17.7bDKK 725.3mDKK 132.6m53.7x133.7x24.4x
Mon, 19 May 2025DKK 15.6bDKK 725.3mDKK 132.6m53.5x117.7x21.5x
Wed, 16 Apr 2025DKK 14.6bDKK 725.3mDKK 132.6m50.5x110.2x20.1x
Fri, 14 Mar 2025DKK 17.1bDKK 725.3mDKK 132.6m52.8x129.1x23.6x
Sun, 09 Feb 2025DKK 20.0bDKK 683.4mDKK 122.6m57.9x163.5x29.3x
Tue, 07 Jan 2025DKK 18.8bDKK 631.7mDKK 89.8m64.6x209.7x29.8x
Thu, 05 Dec 2024DKK 19.5bDKK 631.7mDKK 89.8m61.1x217.7x30.9x
Sat, 02 Nov 2024DKK 14.1bDKK 631.7mDKK 89.8m52.1x157.6x22.4x
Mon, 30 Sep 2024DKK 15.2bDKK 631.7mDKK 89.8m53.4x169.5x24.1x
Wed, 28 Aug 2024DKK 15.4bDKK 625.4mDKK 97.3m46.2x158.2x24.6x
Fri, 26 Jul 2024DKK 15.7bDKK 606.5mDKK 99.3m45.3x158.1x25.9x
Sun, 23 Jun 2024DKK 13.1bDKK 606.5mDKK 99.3m36.4x132.3x21.7x
Tue, 21 May 2024DKK 11.2bDKK 606.5mDKK 99.3m43.6x112.8x18.5x
Thu, 18 Apr 2024DKK 10.1bDKK 606.5mDKK 99.3m36x102.1x16.7x
Sat, 16 Mar 2024DKK 11.6bDKK 606.5mDKK 99.3m52.4x117.3x19.2x
Mon, 12 Feb 2024DKK 10.6bDKK 605.1mDKK 136.8m55.9x77.7x17.6x
Wed, 10 Jan 2024DKK 9.0bDKK 647.9mDKK 171.7m39.2x52.5x13.9x
Fri, 08 Dec 2023DKK 7.8bDKK 647.9mDKK 171.7m33.1x45.6x12.1x
Sun, 05 Nov 2023DKK 7.7bDKK 647.9mDKK 171.7m32.7x44.6x11.8x
Tue, 03 Oct 2023DKK 7.6bDKK 647.9mDKK 171.7m31.9x44.2x11.7x
Thu, 31 Aug 2023DKK 9.2bDKK 664.8mDKK 172.7m40.8x53.1x13.8x
Sat, 29 Jul 2023DKK 9.3bDKK 660.6mDKK 184.0m196.3x50.6x14.1x
Mon, 26 Jun 2023DKK 9.7bDKK 660.6mDKK 184.0m197.5x52.7x14.7x
Wed, 24 May 2023DKK 9.5bDKK 660.6mDKK 184.0m212x51.7x14.4x
Fri, 21 Apr 2023DKK 6.1bDKK 461.2mDKK 179.7m34.1x34.1x13.3x
Price to Earnings Ratio

34.1x


Total Market Cap: DKK 6.1bTotal Earnings: DKK 179.7mTotal Revenue: DKK 461.2mTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Clinical Research and Equipment Industry Price to Earnings3Y Average 88.9x202420252026
Current Industry PE
    There are only 2 companies in the Danish Life Sciences Tools and Services industry, so there is insufficient data to make an industry-wide assessment of both the PE and PS ratio.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have grown 118% per year over the last three years.
  • Revenues for these companies have grown 89% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Danish Clinical Research and Equipment compare with similar industries?

DK Market2.02%
Healthcare1.05%
Life Sciences-4.23%
Clinical Research and Equipment-4.23%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
No data available

Latest News

GUBRA
DKK 332.00
Gubra
7D
-8.8%
1Y
-13.5%

GUBRA: Obesity Study And Ventures Unit Will Drive Long Term Upside

Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing only marginal adjustments to assumptions such as the discount rate and forward P/E as the basis for this maintained view. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study designed to assess safety, tolerability, pharmacokinetics and preliminary efficacy, including muscle volume and muscle function endpoints, in about 188 participants across multiple indications and patient groups (Key Developments).
CHEMM
DKK 302.60
ChemoMetec
7D
-2.1%
1Y
-36.7%